Disease · MONDO_0004247

peptic ulcer disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. peptic ulcer disease. Diseases, record MONDO_0004247. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004247

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: peptic ulcer disease; Open Targets
Open Targets ID: MONDO_0004247; Open Targets
Other names: Sore in the lining of gastrointestinal tract, acute peptic ulcer with haemorrhage, acute peptic ulcer with haemorrhage and perforation, acute peptic ulcer without haemorrhage and without perforation, peptic ulcer; Open Targets
Disease Ontology: DOID:750; Disease Ontology
MeSH: D010437; MeSH
NCI Thesaurus: C3318; NCI Thesaurus
Highest stage of its drugs: Approval, for 56 of its 76 drugs, from ATC, DailyMed and TTD; Open Targets

Drugs76

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OMEPRAZOLE	CHEMBL1503	Small molecule	Approval	ATC and DailyMed	11	7	7	Drugs and targets
ESOMEPRAZOLE	CHEMBL1201320	Small molecule	Approval	ATC and TTD	7	4	4	Drugs and targets
PANTOPRAZOLE	CHEMBL1502	Small molecule	Approval	ATC	5	4	4	Drugs and targets
LANSOPRAZOLE	CHEMBL480	Small molecule	Approval	ATC	3	1	1	Drugs and targets
RABEPRAZOLE	CHEMBL1219	Small molecule	Approval	ATC	3	1	1	Drugs and targets
REBAMIPIDE	CHEMBL1697771	Small molecule	Approval	ATC	3	1	1	Drugs and targets
NAPROXEN	CHEMBL154	Small molecule	Approval	DailyMed	2	1	0	Drugs and targets
TEGOPRAZAN	CHEMBL4297583	Small molecule	Approval	ATC	2	1	1	Drugs and targets
ATROPINE SULFATE	CHEMBL2146146	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
CARBENOXOLONE	CHEMBL499915	Small molecule	Approval	ATC	3	0	0	Drugs and targets

1 to 10 of 76

See all 76 drugs

Targets24

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ATP4A	Potassium-transporting ATPase	12	Potassium-transporting ATPase blocker; Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	12	Potassium-transporting ATPase blocker; Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/496	Drugs and targets
CHRM1	Muscarinic acetylcholine receptor	9	Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1128	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor	8	Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1131	Drugs and targets
HRH2	Histamine H2 receptor	7	Histamine H2 receptor antagonist	Approval	https://conductscience.org/library/genes/3274	Drugs and targets
NR3C1	Glucocorticoid receptor	5	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS2	Cyclooxygenase	4	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
CHRM2	Muscarinic acetylcholine receptor	3	Muscarinic acetylcholine receptor M2 antagonist; Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1129	Drugs and targets
PTGS1	Cyclooxygenase	3	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/153	Drugs and targets

1 to 10 of 24

See all 24 targets

Trials23

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02235311	Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed	Not applicable	3	2017-07-02	Upper Gastrointestinal Bleed	PANTOPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01888588	Risk of Uncomplicated Peptic Ulcer in the General Population		4,000		Peptic Ulcer [Iowa Type (107680.0010)]	ASPIRIN	Its record names the disease	ClinicalTrials.gov
NCT04810793	The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure		820		Helicobacter Pylori	AMOXICILLIN, ESOMEPRAZOLE, FURAZOLIDONE, LEVOFLOXACIN, TETRACYCLINE, VONOPRAZAN FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT00164866	Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy	Phase 4	638		Peptic Ulcer	OMEPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00374101	High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding	Phase 3	450		Peptic Ulcers, Upper Gastrointestinal Bleeding	OMEPRAZOLE, PANTOPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01760824	Quadruple Versus Sequential Therapy for Helicobacter Pylori Eradication	Not applicable	391		Helicobacter Pylori Infection	AMOXICILLIN, BISMUTH SUBCITRATE, CLARITHROMYCIN, ESOMEPRAZOLE, METRONIDAZOLE, TETRACYCLINE	Its record names the disease	ClinicalTrials.gov
NCT05035186	Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era	Not applicable	233		Helicobacter Pylori Infection	AMOXICILLIN, CLARITHROMYCIN, ESOMEPRAZOLE, LEVOFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT01037491	Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets	Not applicable	200		Gastric Ulcer, Duodenal Ulcer	ASPIRIN, CLOPIDOGREL, RABEPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT04061447	Tailored Juice-guided Eradication Therapy	Not applicable	182		Helicobacter Pylori Infection	CLARITHROMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00120315	Proton Pump Inhibitor Treatment Stop	Phase 4	171		Dyspepsia	ESOMEPRAZOLE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 23

See all 23 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36670359	DERIVED	1	PubMed
26246908	DERIVED	1	PubMed
24295850	DERIVED	1	PubMed
21726257	DERIVED	1	PubMed
21305536	DERIVED	1	PubMed
19086953	DERIVED	1	PubMed
18407271	DERIVED	1	PubMed
17442905	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004247

GET https://conductscience.org/api/diseases/v1/MONDO_0004247/drugs?page=2

API reference For AI assistants